TX-SONAR
10.6.2024 15:01:28 CEST | Business Wire | Press release
Sonar, the leader in Clean Code solutions, today announced the expansion of its collaboration with Amazon Web Services (AWS) to help enterprises achieve high-quality code that is clean. SonarCloud, Sonar’s SaaS offering, will be available as an integration with Amazon CodeCatalyst, a unified software development service. Additionally, SonarCloud is now certified by the AWS Foundational Technical Review (FTR) – a set of guidelines to reduce risks around security, reliability, and operational excellence, as defined by the AWS Well-Architected Framework.
“With SonarCloud we enabled our engineering teams to drive consistent code quality and standards across the whole organization. The easy integration into our development toolchain and the simple UI allow us to scale fast and without any issues. The wide adoption and the excellent customer support help you overcome any difficulties,” said Andre Ostermeier, Lead Solutions Architect at Relayr. “Besides that, SonarCloud is an excellent tool to drive Engineering KPIs and should not be underestimated by IT leaders.”
SonarCloud and Amazon CodeCatalyst: Improving Development Processes
Amazon CodeCatalyst features blueprint capabilities that allow customers to automatically set up everything they need to start a new software development project, including continuous integration and delivery (CI/CD) pipelines, deployable code, issue tracking, and fully configured AWS services.
“Customers building apps need to release code early and often, and with solid DevOps practices and tools,” said Nicolas Pujol, ISV Partner Management Leader in EMEA, AWS. “Sonar has done a great job giving developers and DevOps leaders solutions to be more productive, and we’re excited to collaborate to make these tools available to AWS customers.”
Amazon CodeCatalyst paired with Sonar’s unique Clean as You Code approach, delivered through SonarCloud, empowers developers to spend more time writing innovative code and less time managing local development environments. With SonarCloud integrated into Amazon CodeCatalyst CI/CD workflows, development teams can more easily ensure that only clean code will be added to their code base, improving the overall quality of the code written.
Sonar Puts Customer Experience First
Sonar achieved the AWS Foundational Technical Review (FTR) certification by demonstrating that SonarCloud meets best practices critical for a customer’s success. SonarCloud allows for shared expectations across teams rooted in clean code practices, automates code quality checks, and provides extensive feedback for issue resolution.
Sonar’s Clean as You Code Approach
The Clean as You Code approach enables developers and organizations to improve development velocity, code quality, and code security. This simple yet powerful methodology progressively improves the overall quality of the entire codebase as the code is written, with minimal cost and effort. Clean as You Code puts developers in the driver's seat where they take full ownership of the quality of the code they write.
“An increasing number of developers are writing code and building apps in the cloud. We created SonarCloud to provide these developers an easy way to achieve a state of Clean Code, designing a tool that seamlessly integrates with DevOps platforms,” said Fabrice Bellingard, VP of Products at Sonar. “Our growing collaboration with AWS will help more cloud-based development teams create high-quality code with our unique Clean as You Code methodology.”
Today, SonarCloud has over 100,000 active users. The solution has helped a wide range of organizations clean over 2.5 billion lines of code. SonarCloud is free to use on open-source projects. To learn more about SonarCloud, visit here.
About Sonar
Sonar's Clean Code solutions, SonarQube, SonarCloud, and SonarLint, help developers prevent code quality and security issues from ever reaching production. Sonar analyzes all code, regardless of who writes it—your internal team or genAI—resulting in more secure, reliable, and maintainable software. Rooted in the open source community, Sonar’s solutions support over 30 programming languages, frameworks, and infrastructure technologies. Today, Sonar is used by 7M+ developers and 400K organizations worldwide, including the DoD, Microsoft, NASA, MasterCard, Siemens, and T-Mobile.
To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610167595/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom